Product Revenue: Increased 97% to $4.7 million for the first six months of fiscal 2025. Product Gross Margin: Increased to 57.9% for the first half of fiscal 2025, more than double from fiscal 2024. License Revenue: $3 million recognized in the first six months of fiscal 2025 from Zimmer distribution agreement. Net Loss: Improved to $0.5 million for the first six months of fiscal 2025, compared to $6.2 million in the same period of fiscal 2024. Operating Expenses: Decreased 4% to $6.7 million for the first six months of fiscal 2025. Cash and Cash Equivalents: $1.3 million as of March 31, 2025. Working Capital: $2 million as of March 31, 2025. No Debt: The company had no debt outstanding as of March 31, 2025. Capital Raise: $8.2 million in net proceeds from an oversubscribed capital raise in April. Fiscal Year 2025 Guidance: Product revenue expected to be $8 million to $10 million, with gross margin between 47% and 51%.

Warning! GuruFocus has detected 2 Warning Signs with NMTC.

Release Date: May 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

NeuroOne Medical Technologies Corp (NASDAQ:NMTC) reported a 97% increase in product revenue to $4.7 million for the first half of fiscal 2025. The company achieved a significant improvement in product gross margins, reaching 57.9%, more than double the margin from the previous year. NeuroOne Medical Technologies Corp (NASDAQ:NMTC) has no debt and anticipates being fully funded through at least fiscal year 2026. The OneRF ablation system has shown clinical success, with the majority of patients treated remaining seizure-free. The company has expanded its strategic partnership with Zimmer Biomet, leveraging their extensive distribution network to drive product adoption.

Negative Points

Product revenue in the second quarter of fiscal 2025 remained flat at $1.4 million compared to the same quarter in the previous year. The company experienced a sequential decline in product revenue due to the completion of initial stocking orders to Zimmer Biomet. Operating expenses increased slightly to $3.5 million in the second quarter of fiscal 2025. NeuroOne Medical Technologies Corp (NASDAQ:NMTC) reported a net loss of $2.3 million for the second quarter of fiscal 2025. The company has not yet commercialized its products in international markets, representing an untapped revenue opportunity.

Q & A Highlights

Q: On the guidance, you're talking about $8 million to $10 million, and that's excluding the $3 million from the first quarter, correct? A: Yes, that is correct. That does exclude the licensing fee that we received in the first quarter. - Ron McClurg, CFO

Story Continues

Q: Do you expect any revenue to be outside of the deal with Zimmer Biomet for this current year? A: It is almost entirely from Zimmer Biomet. For the first half of the year, about 6% of our revenue was from some of the early centers, but going forward, we expect all of our revenue to be from the Zimmer upgrade. - Ron McClurg, CFO

Q: Can you give us a sense of pro forma cash now? A: At the end of April, we had $9.4 million, which was the cash on hand that included the financing we did with Ladenburg. - Ron McClurg, CFO

Q: Could you talk about adding a Chief Medical Advisor this week and what you anticipate to achieve from that for the company? A: We are excited to have Dr. Patil, whose clinical background fits perfectly into the areas we're in or looking to move into. He will help with product development and clinical requirements. One of the first things we want to do is get a registry to track patient outcomes treated with our ablation system. - David Rosa, CEO

Q: What are your closing remarks regarding the company's current position and future outlook? A: We are a larger, more mature company focusing on ramping revenues and expanding product margins. With a world-class strategic partner and necessary capital, we are poised to execute on strategic growth initiatives and increase shareholder value. - David Rosa, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments